RESUMEN
INTRODUCTION: CD55, a glycosylphosphatidylinositol-anchored, complement-regulating protein (decay-accelerating factor), is expressed by fibroblast-like synoviocytes (FLS) with high local abundance in the intimal lining layer. We here explored the basis and consequences of this uncommon presence. METHODS: Synovial tissue, primary FLS cultures, and three-dimensional FLS micromasses were analyzed. CD55 expression was assessed by quantitative polymerase chain reaction (PCR), in situ hybridization, flow cytometry, and immunohistochemistry. Reticular fibers were visualized by Gomori staining and colocalization of CD55 with extracellular matrix (ECM) proteins by confocal microscopy. Membrane-bound CD55 was released from synovial tissue with phospholipase C. Functional consequences of CD55 expression were studied in the K/BxN serum transfer model of arthritis using mice that in addition to CD55 also lack FcγRIIB (CD32), increasing susceptibility for immune complex-mediated pathology. RESULTS: Abundant CD55 expression seen in FLS of the intimal lining layer was associated with linearly oriented reticular fibers and was resistant to phospholipase C treatment. Expression of CD55 colocalized with collagen type I and III as well as with complement C3. A comparable distribution of CD55 was established in three-dimensional micromasses after ≥3 weeks of culture together with the ECM. CD55 deficiency did not enhance K/BxN serum-induced arthritis, but further exaggerated disease activity in Fcgr2b (-/-) mice. CONCLUSIONS: CD55 is produced by FLS and deposited on the local collagen fiber meshwork, where it protects the synovial tissue against immune complex-mediated arthritis.
Asunto(s)
Complejo Antígeno-Anticuerpo/biosíntesis , Artritis Reumatoide/metabolismo , Antígenos CD55/biosíntesis , Colágeno/metabolismo , Membrana Sinovial/metabolismo , Animales , Artritis Reumatoide/patología , Artritis Reumatoide/prevención & control , Células Cultivadas , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Membrana Sinovial/patologíaRESUMEN
Extensive analysis of a variety of arthritis models in germline KO mice has revealed that all four receptors for the Fc part of IgG (FcγR) play a role in the disease process. However, their precise cell type-specific contribution is still unclear. In this study, we analyzed the specific role of the inhibiting FcγRIIb on B lymphocytes (using CD19Cre mice) and in the myeloid cell compartment (using C/EBPαCre mice) in the development of arthritis induced by immunization with either bovine or chicken collagen type II. Despite their comparable anti-mouse collagen autoantibody titers, full FcγRIIb knockout (KO), but not B cell-specific FcγRIIb KO, mice showed a significantly increased incidence and severity of disease compared with wild-type control mice when immunized with bovine collagen. When immunized with chicken collagen, disease incidence was significantly increased in pan-myeloid and full FcγRIIb KO mice, but not in B cell-specific KO mice, whereas disease severity was only significantly increased in full FcγRIIb KO mice compared with incidence and severity in wild-type control mice. We conclude that, although anti-mouse collagen autoantibodies are a prerequisite for the development of collagen-induced arthritis, their presence is insufficient for disease development. FcγRIIb on myeloid effector cells, as a modulator of the threshold for downstream Ab effector pathways, plays a dominant role in the susceptibility to collagen-induced arthritis, whereas FcγRIIb on B cells, as a regulator of Ab production, has a minor effect on disease susceptibility.
Asunto(s)
Artritis Experimental/inmunología , Autoanticuerpos/inmunología , Linfocitos B/inmunología , Células Mieloides/inmunología , Receptores de IgG/inmunología , Animales , Artritis Experimental/genética , Artritis Experimental/patología , Autoanticuerpos/genética , Linfocitos B/patología , Bovinos , Pollos , Colágeno Tipo II/inmunología , Ratones , Ratones Noqueados , Células Mieloides/patología , Especificidad de Órganos/genética , Especificidad de Órganos/inmunología , Receptores de IgG/genéticaRESUMEN
The cytokine interleukin 1(IL-1) initiates a wide range of proinflammatory cascades and its inhibition has been shown to decrease inflammation in a variety of diseases. IL-1 receptor accessory protein (IL-1RAcP) is an indispensible part of the IL-1R complex that stabilizes IL-1/IL-1R interaction and plays an important role in the signal transduction of the receptor complex. The soluble form of IL-1RAcP (sIL-1RAcP) contains only the extracellular domain and serves as a natural inhibitor of IL-1 signaling. Therefore, increasing sIL-1RAcP levels might be an attractive therapeutic strategy to inhibit IL-1-driven inflammation. To achieve this we designed specific antisense oligonucleotides (AON), to redirect pre-mRNA IL-1RAcP splicing by skipping of the transmembrane domain encoding exon 9. This would give rise to a novel Δ9IL-1RAcP mRNA encoding a soluble, secreted form of IL-1RAcP, which might have similar activity as natural sIL-1RAcP. AON treatment resulted in exon 9 skipping both in vitro and in vivo. A single dose injection of 10 mg AON/kg body weight induced 90% skipping in mouse liver during at least 5 days. The truncated mRNA encoded for a secreted, soluble Δ9IL-1RAcP protein. IL-1RAcP skipping resulted in a substantial inhibition of IL-1 signaling in vitro. These results indicate that skipping of the transmembrane encoding exon 9 of IL-1RAcP using specific AONs might be a promising therapeutic strategy in a variety of chronic inflammatory diseases.Molecular Therapy - Nucleic Acids (2013) 2, e66; doi:10.1038/mtna.2012.58; published online 22 January 2013.
RESUMEN
Soluble receptors modify the biological response to ligand by competing with their membrane-bound counterparts for the ligand. They act as competitive inhibitors of the signaling by binding to ligands without inducing cellular signal transduction pathways and thus neutralizing the bioactivity of the ligand. Shifting of transmembrane receptors to their soluble isoforms can be manipulated by using antisense oligonucleotide (AON) mediated exon skipping by targeting the exons which encode the transmembrane region and deleting them from the mature transcript. It has been shown that membrane bound receptors of cytokines TNF-α and IL-5 can be successfully converted into soluble forms by AON mediated exon skipping. This approach can be applied for the treatment of other inflammatory diseases or conditions where cytokines play important role by favoring the expression of soluble cytokine receptors inhibiting proinflammatory pathways. With this strategy, decrease in mRNA and protein levels of membrane-bound receptors upon AON treatment can be tested in vitro and in vivo by using the techniques mentioned in this chapter. The efficacy of AONs in producing therapeutic isoforms of the receptors should be tested further in vivo on disease models.
Asunto(s)
Exones , Inflamación/genética , Proteínas de la Membrana/genética , Oligonucleótidos Antisentido/genética , Animales , Western Blotting/métodos , Línea Celular , Electroforesis en Gel de Poliacrilamida/métodos , Terapia Genética/métodos , Humanos , Inflamación/terapia , Masculino , Ratones , Ratones Endogámicos C57BL , FN-kappa B/metabolismo , Reacción en Cadena de la Polimerasa/métodos , Isoformas de Proteínas/genética , ARN/genética , ARN/aislamiento & purificación , TransfecciónRESUMEN
OBJECTIVE: CD55 (decay-accelerating factor) is best known for its role in the negative regulation of the complement system. Indeed, lack of this molecule leads to disease aggravation in many autoimmune disease models. However, CD55 is abundantly present on fibroblast-like synoviocytes and is also a ligand of the adhesion-class heptahelical receptor CD97, which is expressed by infiltrating macrophages. Treatment with antibodies to CD97 ameliorates the collagen-induced model of rheumatoid arthritis (RA) in DBA/1 mice, but the net contribution of CD55 is unknown. This study was undertaken to investigate the role of CD55 in experimental RA. METHODS: Arthritis was induced in wild-type, CD55(-/-), and CD97(-/-) mice using collagen-induced and K/BxN serum-transfer models. Incidence of arthritis was monitored over time, and disease activity was assessed by clinical and immunohistochemical evaluation. RESULTS: In contrast to observations in many inflammatory disease models, lack of CD55 resulted in decreased arthritis in experimental models of RA. Consistent with the previously reported effects of anti-CD97 antibody treatment, CD97(-/-) mice had reduced arthritis activity compared with wild-type controls. CONCLUSION: Our findings indicate that the lack of CD55 or CD97 in 2 different models of arthritis increases resistance to the disease. These findings provide insight into a role for CD55 interaction with CD97 in the pathogenesis of RA and suggest that therapeutic strategies that disrupt CD55/CD97 may be clinically beneficial.